Europe Inhalable Drugs Market Size, Industry Trends, Share and Forecast 2020-2026
The European inhalable drug market is anticipated to grow at a CAGR of 3.3% over the forecast period (2020-2026). The key factors that drive the growth of the market include the support by the key players functioning in the market, rising geriatric population, sedentary lifestyles, along with the change in eating habits of the people. The major countries of Europe considered in the report include the UK, France, Germany, Italy, Spain, and the Rest of Europe.
To Request a Sample of our Report on Europe Inhalable
Drugs Market: https://www.omrglobal.com/request-sample/europe-inhalable-drugs-market
The UK is considered a promising market for the
European inhalable drug industry. According to Diabetes UK, in 2019, there were
almost 3.7 million people who were diagnosed with diabetes in the country,
representing 6% of the UK population. This represents 1 in every 16 people with
suffer from diabetes. By 2025, it is estimated that five million people are
likely to suffer from diabetes in the UK, according to Diabetes UK. This
creates demand for inhalable insulin, especially among aged people, and hence
creates scope for market growth.
Besides, the key player's contributions are also
further driving the European market over the forecast period. F. Hoffmann-La
Roche Ltd., Pfizer Inc., Novartis AG, Boehringer Ingelheim GmbH, and
AstraZeneca Plc are some of the players operating in the market in the region.
These players adopt several growth strategies such as product launches,
innovations, mergers, and acquisitions in order to thrive in the competitive
market. For instance, in February 2017, Boehringer Ingelheim Pharmaceuticals
announced that the FDA approved SPIRIVA RESPIMAT, an inhalable spray, for the
long-term, once-daily maintenance treatment of asthma in people age 6 and
older.
Market Coverage
·
Market number available for – 2019-2026
·
Base year- 2019
·
Forecast period- 2020-2026
·
Segment Covered- By Application and By Route of
Administration
·
Regions Covered- Europe
·
Competitive Landscape- F. Hoffmann-La Roche Ltd.,
Novartis International AG, AstraZeneca Plc, Boehringer Ingelheim GmbH, and GlaxoSmithKline
Plc
(Get 15% Discount on Buying this Report)
A
full Report of Europe Inhalable Drugs Market is Available at: https://www.omrglobal.com/industry-reports/europe-inhalable-drugs-market
Europe Inhalable Drugs Market – Segmentation
By Application
·
Respiratory Diseases
·
Non- Respiratory Diseases
By Route of Administration
·
Nasal
·
Mouth
Europe Inhalable Drugs Market – Countries Covered
·
UK
·
Germany
·
France
·
Italy
·
Spain
Rest of Europe
Competitive
Landscape
·
AstraZeneca Plc
·
Overview
·
AstraZeneca Plc in Europe Landscape
·
Recent Developments
·
AstraZeneca Plc in Inhalable Drugs
·
Bausch Health Companies Inc.
·
Boehringer Ingelheim International GmbH
·
F. Hoffmann-La Roche Ltd.
·
GlaxoSmithKline Plc
·
Johnson & Johnson Services Inc.
·
Novartis AG
·
Pfizer Inc.
·
Sanofi SA
·
Vectura Group Plc
·
Verona Pharma plc
·
Zambon S.p.A.
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data, Request for
Report Customization @ https://www.omrglobal.com/report-customization/europe-inhalable-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other research-based
services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment